Fig. 3From: Real-world experience of erenumab in patients with chronic or episodic migraine in the UAEProportion of patients achieving < 50%, 50% to < 75%, 75% to < 100% and 100% reduction in MHD over time. MHD, monthly headache days. Percentages are based on the total number of evaluable subjects at the respective visit in the full analysis setBack to article page